Results 241 to 250 of about 321,312 (283)

Advances in the pathophysiology and treatment of anaemia in multiple myeloma. [PDF]

Curr Opin Hematol
Giuliani N, Dalla Palma B, Notarfranchi L.   +2 more
europepmc   +1 more source

Increasing Trends of Minimal Residual Disease Measurement in Trials Focusing on Multiple Myeloma Treatment: A Systematic Analysis of Clinical Research Design From 2014 to 2025

European Journal of Haematology, EarlyView.
ABSTRACT Minimal residual disease (MRD) is a central biomarker in multiple myeloma (MM), offering unprecedented sensitivity for evaluating treatment efficacy and serving as a potential surrogate endpoint. We conducted a comprehensive analysis of clinical trials registered on ClinicalTrials.gov between 2014 and 2025.
Mimi Choon‐Quinones, George Dennis Obeng, Benjamin Asiedu‐Ayeh, Sampson Kawuo, Asmau Mohammed Tukur, Inusah Mohammed, Akosua Pokuaah Obeng, Jean‐Luc Harousseau, Anja Seckinger, Dirk Hose, Emmanuel Sarkodie, Attila Imre, Marcell Csanádi   +12 more
wiley   +1 more source

Targeting Ikaros and Aiolos: Next‐Generation Cereblon E3 Ligase Modulators in MM

European Journal of Haematology, EarlyView.
The graphical abstract illustrates the mechanism of action of cereblon E3 ligase modulators (CELMoDs) in multiple myeloma, highlighting cereblon‐mediated degradation of IKZF1 and IKZF3. Compared with classical immunomodulatory drugs (IMiDs), CELMoDs induce deeper IKZF1/3 depletion, leading to more pronounced suppression of the IRF4–MYC survival axis ...
Maria Eugenia Alvaro, Enrica Antonia Martino, Santino Caserta, Mamdouh Skafi, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Ernesto Vigna, Fortunato Morabito, Massimo Gentile   +12 more
wiley   +1 more source

Multiple myeloma in adolescents and young adults(AYA): global epidemiological trends, risk factors, and future projections (1990-2040). [PDF]

Cancer Causes Control
Kundu R, Mukhopadhyay A, Sarkar N, Kal N, Pal TS, Soni K, Mukherjee S.   +6 more
europepmc   +1 more source

Risk of Transformation to Acute Myeloid Leukaemia and Myelodysplastic Syndromes in Patients With Myeloproliferative Neoplasms Over Attained Age and Time Since Diagnosis: A Nationwide Cohort Study

European Journal of Haematology, EarlyView.
ABSTRACT Background Individuals with polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) face transformation risks to acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). While older age is linked to increased risk, it remains unclear whether risk increases with age or with disease duration.
Nurgul Batyrbekova, Anna Ravn Landtblom, Malin Hultcrantz, Robert Szulkin, Paul W. Dickman, Therese M.‐L. Andersson   +5 more
wiley   +1 more source

Salvage or Second Autologous SCT in Relapsed Multiple Myeloma (2016-2026): A Decade in Review. [PDF]

Curr Oncol
Nassar M, Alzaidy N, Nasiri A, Hanbali A, Aljurf MA, Mohammed Saleh MF.   +5 more
europepmc   +1 more source

Positioning of Melflufen in Heavily Pretreated RRMM Patients: Real‐World Evidence in a Rapidly Evolving Therapeutic Landscape

European Journal of Haematology, EarlyView.
ABSTRACT Modern therapies have clearly marked the history of multiple myeloma (MM), leading to undisputed advantages in terms of sustained responses and prolonged survival, while progressively improving patients' quality of life. Nonetheless, disease recurrence and resistance to available therapies underscore the importance of identifying additional ...
K. Mancuso, S. Masci, M. Talarico, A. Vitale, S. Barbato, V. Solli, M. Puppi, I. Rizzello, L. Pantani, P. Tacchetti, M. Iezza, R. Restuccia, I. Sacchetti, E. Manzato, S. Ghibellini, S. Armuzzi, B. Taurisano, M. Cavo, E. Zamagni   +18 more
wiley   +1 more source

Translation approaches to support systemic anti-cancer therapy consent for individuals with limited English proficiency. [PDF]

Support Care Cancer
Hibbs SP, Nizam R, Tanzim U, Aiken L, Habib S, Hodgson S, Williams J, Januszewski A, Hantel A, Uddin MS, Isaacs T, Bajaj B, Cockburn O, Islam A, Pratt G, Federici FM.   +15 more
europepmc   +1 more source

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study

Blood Cancer Journal
Fan Yang, Rui Liu, Zhonghua Fu, Yuelu Guo, Lixia Ma, Miaomiao Cao, Biping Deng, Alex H. Chang, Haifeng Wu, Shilin Gan, Chen Chen, Xiaoyan Ke, Kai Hu   +12 more
doaj   +1 more source

Light Chain Deposition Disease and Light Chain Cast Nephropathy in a Patient With Multiple Myeloma and HIV Infection: A Case Report. [PDF]

Case Rep Nephrol
Huisamen T, Coetzee L, Chothia MY.
europepmc   +1 more source